Market Overview

JMP Securities Comments On Salix Pharmaceutical's Takeover Valuation


Following Valeant Pharmaceutical’s (NYSE: VRX) Acquisition of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), analysts at JMP Securities offered commentary on the deal.

Within the note, Oren Livnat wrote, “Salix Pharmaceuticals has agreed to be acquired by Valeant for ~$14.5B cash ($158/share), a valuation below some expectations but, in our view, likely close to the best offer Salix will receive.”

Given that Salix has been in acquisition talks for the past few months, Livnat suspects that the $158 per share price is close to where a deal would have been reached under any circumstance, especially as Salix faces FDA risk from the upcoming PDUFA date for Xifaxan.

According to Livnat, the $158 per share value is 17.6 times Salix’s 2016 EPS guidance, “which is below where other recent Spec Pharma acquisitions priced.”

Shares of Salix Pharmaceuticals traded recently at $155.91, down 1.2 percent.

Latest Ratings for SLXP

Mar 2015JefferiesDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral
Feb 2015Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: JMP Securities Oren G. LivnatAnalyst Color M&A Analyst Ratings


Related Articles (SLXP + VRX)

View Comments and Join the Discussion!

NY Soft Commodities Mostly Lower

Runaway Bull Stampede In Apple: A Technical Look